2024-08-01 2025-07-31 false Capium Accounts Production 1.1 14216049 2024-08-01 2025-07-31 14216049 bus:AbridgedAccounts 2024-08-01 2025-07-31 14216049 bus:FRS102 2024-08-01 2025-07-31 14216049 bus:AuditExemptWithAccountantsReport 2024-08-01 2025-07-31 14216049 bus:SmallCompaniesRegimeForAccounts 2024-08-01 2025-07-31 14216049 bus:PrivateLimitedCompanyLtd 2024-08-01 2025-07-31 14216049 2024-08-01 2025-07-31 14216049 2025-07-31 14216049 bus:RegisteredOffice 2024-08-01 2025-07-31 14216049 core:WithinOneYear 2025-07-31 14216049 core:AfterOneYear 2025-07-31 14216049 1 2024-08-01 2025-07-31 14216049 bus:Director1 2024-08-01 2025-07-31 14216049 bus:Director1 2025-07-31 14216049 bus:Director1 2023-08-01 2024-07-31 14216049 2023-08-01 14216049 bus:LeadAgentIfApplicable 2024-08-01 2025-07-31 14216049 2023-08-01 2024-07-31 14216049 2024-07-31 14216049 core:WithinOneYear 2024-07-31 14216049 core:AfterOneYear 2024-07-31 14216049 bus:EntityAccountantsOrAuditors 2023-08-01 2024-07-31 14216049 bus:OrdinaryShareClass1 2024-08-01 2025-07-31 14216049 bus:OrdinaryShareClass1 2025-07-31 14216049 bus:OrdinaryShareClass1 2023-08-01 2024-07-31 14216049 bus:OrdinaryShareClass1 2024-07-31 14216049 core:CostValuation core:Non-currentFinancialInstruments 2025-07-31 14216049 core:CostValuation core:Non-currentFinancialInstruments 2024-07-31 14216049 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2025-07-31 14216049 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2025-07-31 14216049 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-07-31 14216049 core:Non-currentFinancialInstruments 2025-07-31 14216049 core:Non-currentFinancialInstruments 2024-07-31 14216049 core:ShareCapital 2025-07-31 14216049 core:ShareCapital 2024-07-31 14216049 core:RetainedEarningsAccumulatedLosses 2025-07-31 14216049 core:RetainedEarningsAccumulatedLosses 2024-07-31 14216049 dpl:Item1 2024-08-01 14216049 dpl:Item1 2025-07-31 14216049 dpl:Item1 2023-08-01 14216049 dpl:Item1 2024-07-31 iso4217:GBP xbrli:shares xbrli:pure

Registered Number: 14216049
England and Wales
NRT PHARMA LTD
Abridged Accounts
Period of accounts Start date: 01 August 2024 End date: 31 July 2025

NRT PHARMA LTD Contents Page For the year ended 31 July 2025
Statement of financial position | 1
Notes to the financial statements | 2

NRT PHARMA LTD Statement of Financial Position As at 31 July 2025
| Notes | 2025 £ |  | 2024 £
--- | --- | --- | --- | ---
Current assets |  |  |
Cash at bank and in hand |  | 13,616 |  | 18,504
Creditors: amount falling due within one year |  | (10,528) |  | (15,204)
Net current assets |  | 3,088 |  | 3,300
Total assets less current liabilities |  | 3,088 |  | 3,300
Net assets |  | 3,088 |  | 3,300
Capital and reserves |  |  |
Called up share capital | 3 | 1 |  | 1
Profit and loss account |  | 3,087 |  | 3,299
Shareholders' funds |  | 3,088 |  | 3,300
For the year ended 31 July 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. Director's responsibilities: The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476. The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered to the Registrar of Companies. The members have agreed to the preparation of abridged accounts for this accounting period in accordance with section 444(2A). The financial statements were approved by the director on 20 January 2026 and were signed by:
------------------------------- Nikita Piush PATEL Director
1

NRT PHARMA LTD Notes to the Abridged Financial Statements For the year ended 31 July 2025
General Information NRT PHARMA LTD is a private company, limited by shares, registered in England and Wales, registration number 14216049, registration address 39 Marne Avenue, London, N11 1JU. The presentation currency is £ sterling.
1. | Accounting policies Significant accounting policies Statement of compliance These financial statements have been prepared in compliance with FRS 102 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006. Basis of preparation The financial statements have been prepared under the historical cost convention as modified by the revaluation of land and buildings and certain financial instruments measured at fair value in accordance with the accounting policies. The financial statements are prepared in sterling which is the functional currency of the company. Turnover Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts. Taxation Taxation represents the sum of tax currently payable and deferred tax. Tax is recognised in the statement of income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. The company’s liability for current tax is calculated using the tax rates and laws that have been enacted or substantively enacted at the reporting date. Current and deferred tax assets and liabilities are not discounted Dividends Proposed dividends are only included as liabilities in the statement of financial position when their payment has been approved by the shareholders prior to the statement of financial position date. Provisions Provisions are recognised when the company has a present obligation as a result of a past event which it is more probable than not will result in an outflow of economic benefits that can be reasonably estimated.
2. | Average number of employees Average number of employees during the year was 1 (2024 : 1).
3. | Share Capital
Allotted, called up and fully paid | 2025 £ |  | 2024 £
--- | --- | --- | ---
1 Class A share of £1.00 each | 1 |  | 1
| 1 |  | 1
2